Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...

Eli Lilly’s weight loss drug Zepbound led to significantly greater weight loss than Novo Nordisk’s Wegovy in a 72-week, head-to-head clinical trial, according to findings published in The New England ...

Eli Lilly announced that its obesity drug Zepbound outperformed Novo Nordisks Wegovy in a direct comparison across five key ...

Those research findings ... the research showing an advantage for Zepbound, Mr. Whitrap said that both drugs are highly effective and that clinical trial results often differ from the results ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average ... who led the study and presented the findings Sunday at the European Congress on Obesity in Spain.